ŗ£½ĒĘƽā°ę

StemSpanā„¢ Lymphoid Differentiation Coating Material (100X)

Coating material for the expansion and differentiation of lymphoid cells

StemSpanā„¢ Lymphoid Differentiation Coating Material (100X)

Coating material for the expansion and differentiation of lymphoid cells

Catalog #
(Select a product)
Coating material for the expansion and differentiation of lymphoid cells
Request Pricing Request Pricing

Overview

Use StemSpanā„¢ Lymphoid Differentiation Coating Material (100X) to coat plates for the expansion and differentiation of human CD34+ hematopoietic progenitor cells to T cells.

For your convenience, this supplement is available either individually or as part of the StemSpanā„¢ T Cell Generation Kit or the STEMdiffā„¢ T Cell Kit. In this protocol, CD34+ cells are first differentiated to CD7+CD5+ lymphoid progenitor cells, using StemSpanā„¢ Lymphoid Progenitor Expansion Supplement (10X), and then further directed to differentiate to DP T cells.

StemSpanā„¢ Lymphoid Differentiation Coating Material (100X) is intended for use in combination with StemSpanā„¢ T Cell Progenitor Maturation Supplement (10X), StemSpanā„¢ SFEM II medium, and StemSpanā„¢ Lymphoid Progenitor Expansion Supplement (10X).

For detailed information on protocols for expansion and differentiation of CD34+ cells with StemSpanā„¢, please explore the Technical Manual and Educational Materials.
Subtype
Supplements
Cell Type
Hematopoietic Stem and Progenitor Cells
Species
Human
Application
Cell Culture
Brand
StemSpan
Area of Interest
Cancer, Drug Discovery and Toxicity Testing, Immunology, Stem Cell Biology, Cell Therapy Development
Formulation Category
Serum-Free

Data Figures

Figure 1. Frequency and Yield of CD7+CD5+ Pro-T Cells After 14 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured for 14 days in StemSpanā„¢ SFEM II containing Lymphoid Progenitor Expansion Supplement (Catalog #09915) on plates coated with Lymphoid Differentiation Coating Material (Catalog #09925). Cells were harvested and analyzed for CD7 and CD5 expression by (A) flow cytometry. The (B) average frequency of viable CD7+CD5+ pro-T cells on day 14 was 70%, with ~200 CD7+CD5+ cells produced per input CD34+ cell. Shown are means with 95% confidence intervals (n = 33).

Figure 2. Frequency and Yield of CD4 ISP and CD4+CD8+ DP Cells After 42 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured with the StemSpanā„¢ T Cell Generation Kit (Catalog #09940) for 42 days and (A) analysed by flow cytometry for the expression of CD4, CD8, CD3 and °Õ°äøéαβ. The (B) frequency and (C) yield of CD4 ISP, double-positive (CD4+CD8+) and CD3+°Õ°äøéαβ+-expressing double-positive cells (CD4+CD8+CD3+°Õ°äøéαβ+) are shown. On average, 38% of the total viable population were DP (CD4+CD8+), of which 35% co-expressed CD3 and °Õ°äøéαβ. The yields of total DP cells and CD3+°Õ°äøéαβ+ DP cells per input CD34+ cell were ~23,000 and ~9,000, respectively. Shown are means with 95% confidence intervals (n = 31).

Figure 3. Frequency and Yield of CD8 SP T Cells After 49 Days of Culture

DP cells were further matured into CD8 SP T cells by culturing for an additional 7 days in StemSpanā„¢ SFEM II with T Cell Progenitor Maturation Supplement (Catalog #09930), IL-15 (Catalog #78031) and ImmunoCultā„¢ CD3/CD28/CD2 T Cell Activator (Catalog #10970) on coated plates. On day 49, cells were (A) analyzed by flow cytometry for the expression of CD3, °Õ°äøéαβ, CD4 and CD8. The (B) frequency and yield of CD3+°Õ°äøéαβ+-expressing cells and their subsets are shown. On average, 54% of the CD3+°Õ°äøéαβ+ cells were DP (CD4+CD8+) and 38% were CD8 SP (CD4-CD8+). The average yield of CD8 SP T cells per input CD34+ cell was ~6,000. CD3+°Õ°äøéαβ+ CD4 SP (CD4+CD8-) T cells were detected at very low frequencies (data not shown). Shown are means with 95% confidence intervals (n = 12).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
09925
Lot #
All
Language
English
Document Type
Product Name
Catalog #
09925
Lot #
All
Language
English
Document Type
Product Name
Catalog #
09925
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (2)

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity Li et al. Journal of Hematology & Oncology 2025 Oct

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of ER, PR, and HER2 expression. Its aggressive behavior, high degree of tumor heterogeneity, and immunosuppressive tumor microenvironment (TME) are associated with poor clinical outcomes, rapid disease progression, and limited therapeutic options. Although chimeric antigen receptor (CAR)-engineered T cell therapy has shown certain promise, its applicability in TNBC is hindered by antigen escape, TME-mediated suppression, and the logistical constraints of autologous cell production. In this study, we employed hematopoietic stem and progenitor cell (HSPC) gene engineering and a feeder-free HSPC differentiation culture to generate allogeneic IL-15-enhanced, mesothelin-specific CAR-engineered invariant natural killer T ( Allo15 MCAR-NKT) cells. These cells demonstrated robust and multifaceted antitumor activity against TNBC, mediated by CAR- and NK receptor-dependent cytotoxicity, as well as selective targeting of CD1d + TME immunosuppressive cells through their TCR. In both orthotopic and metastatic TNBC xenograft models, Allo15 MCAR-NKT cells demonstrated potent antitumor activity, associated with robust effector and cytotoxic phenotypes, low exhaustion, and a favorable safety profile without inducing graft-versus-host disease. Together, these results support Allo15 MCAR-NKT cells as a next-generation, off-the-shelf immunotherapy with strong therapeutic potential for TNBC, particularly in the context of metastasis, immune evasion, and treatment resistance. The online version contains supplementary material available at 10.1186/s13045-025-01736-9.
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies Li et al. Nature Communications 2025 Feb

Abstract

Chimeric antigen receptor (CAR)-engineered T cell therapy holds promise for treating myeloid malignancies, but challenges remain in bone marrow (BM) infiltration and targeting BM-resident malignant cells. Current autologous CAR-T therapies also face manufacturing and patient selection issues, underscoring the need for off-the-shelf products. In this study, we characterize primary patient samples and identify a unique therapeutic opportunity for CAR-engineered invariant natural killer T (CAR-NKT) cells. Using stem cell gene engineering and a clinically guided culture method, we generate allogeneic CD33-directed CAR-NKT cells with high yield, purity, and robustness. In preclinical mouse models, CAR-NKT cells exhibit strong BM homing and effectively target BM-resident malignant blast cells, including CD33-low/negative leukemia stem and progenitor cells. Furthermore, CAR-NKT cells synergize with hypomethylating agents, enhancing tumor-killing efficacy. These cells also show minimal off-tumor toxicity, reduced graft-versus-host disease and cytokine release syndrome risks, and resistance to allorejection, highlighting their substantial therapeutic potential for treating myeloid malignancies. Subject terms: Cancer therapy, Immunotherapy, Leukaemia